Dean A. Falb

63 year

Health Technology

Consumer Services

Profile

Dean A.
Falb worked as Vice President-Research & Development at Stryker Corp.
from 2005 to 2012.
He also worked as Senior Vice President-Research & Development at Praecis Pharmaceuticals, Inc. and as Chief Scientific Officer at LogicBio Therapeutics, Inc. In 2013, he became the Chief Technology Officer at Synlogic, Inc. Dr. Falb holds a doctorate degree from Harvard University and an undergraduate degree from Purdue University.

Former positions of Dean A. Falb

Companies	Position	End
SYNLOGIC, INC.	Chief Tech/Sci/R&D Officer	2018-04-30
STRYKER CORPORATION	Chief Tech/Sci/R&D Officer	2011-12-31
LOGICBIO THERAPEUTICS, INC.	Chief Tech/Sci/R&D Officer	-
Praecis Pharmaceuticals, Inc. Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA.	Chief Tech/Sci/R&D Officer	-

See the detail of Dean A. Falb's experience

Training of Dean A. Falb

Harvard University	Doctorate Degree
Purdue University	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Dean A. Falb's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
SYNLOGIC, INC.	Health Technology
STRYKER CORPORATION	Health Technology

Private companies	2
Praecis Pharmaceuticals, Inc. Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA.	Health Technology
LogicBio Therapeutics, Inc. LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA.	Health Technology